NCT01522391已完成1 期
A Randomized, Double-blinded Placebo-controlled Study to Investigate Antimicrobial Efficacy and Safety Following Topical Application of DPK-060
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- DermaGen AB
- 入组人数
- 41
- 试验地点
- 1
- 主要终点
- Percent Change From Baseline in Total Microbial Colony Forming Units (CFU) Count at Day 14 Full Analysis Set
研究概览
简要总结
The primary objective of this study was to evaluate microbial density in eczematous lesions during two weeks of twice daily therapy with the investigational product, DPK-060 1% ointment, compared with placebo in patients with atopic dermatitis. This randomized, double-blind, placebo-controlled part of the study was preceded with an open-label investigation in a small group of patients (n=5) treated with two applications of DPK-060 1% ointment per day for four days to assess safety, local tolerability and systemic absorption of DPK-060.
The secondary objectives were to evaluate severity of eczema and pruritus, to assess the tolerability and safety of the treatment and to assess the degree of systemic absorption of DPK-060 in blood on Day 7 and Day 21 in a sub-set of 10 patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A clinical diagnosis of atopic dermatitis
- •Treatable eczematous lesions of a total area of at least 25 cm2 (100 cm2 for the initial five patients)
- •Female patients of childbearing potential had to be using an appropriate method of contraception.
- •Female patients of childbearing potential were not eligible before PK data from the first 10 patients had been evaluated and the Medical Products Agency (Swedish regulatory agency) had given approval to include women of childbearing potential.
排除标准
- •Significant clinical illness, within the two weeks prior to first dose, which could affect the outcome of the study
- •Previous local or systemic antimicrobial therapy within the last four weeks prior to the first application of the investigational product (DPK-060 1% or placebo ointment)
- •Existence of any surgical or medical condition which, in the judgment of the investigator, might interfere with the absorption, distribution, metabolism or excretion of the drug
- •Patients who had had systemic treatment for atopic dermatitis or other topical or transdermal treatments (such as nicotine, hormone replacement therapies)on the site of eczema within 14 days prior to first application of DPK-060 1% or placebo ointment and/or topical treatment with tar, any corticosteroid,topical immunomodulators or oral treatment with any corticosteroids within 14 days prior to first application and/or oral antihistamines within 14 days of the first dose.
- •A need for any other medication during the period 0 to 7 days before entry to the study, (excluding the oral contraceptive pill for females) except those deemed by the principal investigator / clinical investigator not to interfere with the outcome of the study
- •Diagnosis of other skin diseases, which in the opinion of the investigator, were likely to adversely affect the outcome of the study
- •History or evidence of significant cardiac, renal, hepatic or endocrine disease
- •Significant hypersensitivity or allergy, as judged by the investigator
- •Immunocompromised patients
- •Lice or scabies
- •Tinea corporis
- •Hypersensitivity to the ingredients of the vehicle
- •The presence of prominent tattoos at sites of application of DPK-060 1% or placebo ointment
- •Donation of blood, exceeding 450 mL, during the three months prior to first dose
- •Participation in a clinical study during the 12 weeks prior to first dose
- •Ongoing alcohol or drug abuse
- •Positive pregnancy test or lactation
研究组 & 干预措施
DPK-060 1% ointment
Experimental
干预措施: DPK-060 1% ointment (Drug)
Placebo for DPK-060 ointment
Placebo Comparator
干预措施: Placebo for DPK-060 ointment (Drug)
结局指标
主要结局
Percent Change From Baseline in Total Microbial Colony Forming Units (CFU) Count at Day 14 Full Analysis Set
时间窗: Baseline and Day 14
The total microbial colony forming units count is the number of CFU/cm2 for total microbial count in eczematous lesions.
Percent Change From Baseline in Total Microbial Colony Forming Units (CFU) Count at Day 14 Per Protocol Analysis Set
时间窗: Baseline and Day 14
The total microbial colony forming units count is the number of CFU/cm2 for total microbial count in eczematous lesions.
次要结局
- Percent Change From Baseline in KNS CFU Count at Day 7, 14 and 21 Full Analysis Set(Baseline, Day 7, Day 14 and Day 21)
- Percent Change From Baseline in Total Microbial Colony Forming Units (CFU) Count at Day 7 and 21 Per Protocol Analysis Set(Baseline, Day 7 and 21)
- Percent Change From Baseline in S.Aureus CFU Count at Day 7, 14 and 21 Full Analysis Set(Baseline, Day 7, Day 14 and Day 21)
- Percent Change From Baseline in Total Microbial Colony Forming Units (CFU) Count at Day 7 and 21 Full Analysis Set(Baseline, Day 7 and 21)
- Percent Change From Baseline in KNS CFU Count at Day 7, 14 and 21 Per Protocol Analysis Set(Baseline, Day 7, Day 14 and Day 21)
- Percent Change From Baseline in Gram-positive Bacteria CFU Count at Day 7, 14 and 21 Full Analysis Set(Baseline, Day 7, Day 14 and Day 21)
- Percent Change From Baseline in Gram-positive Bacteria CFU Count at Day 7, 14 and 21 Per Protocol Analysis Set(Baseline, Day 7, Day 14 and Day 21)
- Change in Total Treated Eczema Area Full Analysis Set(Baseline, Day 7, Day 14 and Day 21)
- Change in Total Treated Eczema Area Per Protocol Analysis Set(Baseline, Day 7, Day 14 and Day 21)
- Erythema Eczema Area and Severity Index (EASI) Full Analysis Set(Day 7, Day 14 and Day 21)
- Excoriations Eczema Area and Severity Index (EASI) Per Protocol Analysis Set(Day 7, Day 14 and Day 21)
- Infiltration Eczema Area and Severity Index (EASI) Per Protocol Analysis Set(Day 7, Day 14 and Day 21)
- Percent Change From Baseline in S.Aureus CFU Count at Day 7, 14 and 21 Per Protocol Analysis Set(Baseline, Day 7, Day 14 and Day 21)
- Change in Area of Microbial Counting Site Full Analysis Set(Baseline, Day 7, Day 14 and Day 21)
- Erythema Eczema Area and Severity Index (EASI) Per Protocol Analysis Set(Day 7, Day 14 and Day 21)
- Lichenification Eczema Area and Severity Index (EASI) Full Analysis Set(Day 7, Day 14 and Day 21)
- Lichenification Eczema Area and Severity Index (EASI) Per Protocol Analysis Set(Day 7, Day 14 and Day 21)
- Investigator's Global Assessment of Eczema Change Full Analysis Set(Day 7, Day 14 and Day 21)
- Investigator's Global Assessment of Eczema Change Per Protocol Analysis Set(Day 7, Day 14 and Day 21)
- Change in Area of Microbial Counting Site Per Protocol Analysis Set(Baseline, Day 7, Day 14 and Day 21)
- Excoriations Eczema Area and Severity Index (EASI) Full Analysis Set(Day 7, Day 14 and Day 21)
- Infiltration Eczema Area and Severity Index (EASI) Full Analysis Set(Day 7, Day 14 and Day 21)
- Change From Baseline in Visual Analog Scale of Itching (VASI) Full Analysis Set(Baseline, Day 7, Day 14 and Day 21)
- Change From Baseline in Visual Analog Scale of Itching (VASI) Per Protocol Analysis Set(Baseline, Day 7, Day 14 and Day 21)
- Patient's Global Assessment of Eczema Change Full Analysis Set(Day 7, Day 14 and Day 21)
- Patient's Global Assessment of Eczema Change Per Protocol Analysis Set(Day 7, Day 14 and Day 21)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic DermatitisAtopic DermatitisNCT04413942Oneness Biotech Co., Ltd.99
已完成
4 期
Study of the Combination of a Cyanoacrylate and Surgical Solutions in Reducing Skin Flora ContaminationSkin Flora ContaminationNCT00467857Kimberly-Clark Corporation293
已完成
1 期
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical PropertiesPapulopustular RosaceaNCT05675501Sol-Gel Technologies, Ltd.31
已完成
2 期
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary DiseaseNontuberculous Mycobacterial Pulmonary Disease (NTM-PD)NCT05496374Spero Therapeutics25
Unknown
不适用
Assessment of the Effects on the Skin Microbiome of Amending an Over-the-counter Eczema Product With Activated Oil (AO)EczemaNCT05413395GlycosBio, Inc.60